Bjøro K - Search Results

1

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.

Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. Moghaddam A, et al. Among authors: bjoro k. Hepatology. 2011 Mar;53(3):746-54. doi: 10.1002/hep.24154. Hepatology. 2011. PMID: 21374656 Clinical Trial.

2

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.

Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. Dalgard O, et al. Among authors: bjoro k. Hepatology. 2004 Dec;40(6):1260-5. doi: 10.1002/hep.20467. Hepatology. 2004. PMID: 15558712 Clinical Trial.

3

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.

Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H; North-C Group. Dalgard O, et al. Among authors: bjoro k. Hepatology. 2008 Jan;47(1):35-42. doi: 10.1002/hep.21975. Hepatology. 2008. PMID: 17975791 Clinical Trial.

4

In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.

Dalgard O, Bjoro K, Ring-Larsen H, Verbaan H. Dalgard O, et al. Among authors: bjoro k. Eur J Gastroenterol Hepatol. 2010 May;22(5):552-6. doi: 10.1097/MEG.0b013e328335b29e. Eur J Gastroenterol Hepatol. 2010. PMID: 20154627

5

Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.

Eskesen AN, Melum E, Moghaddam A, Bjøro K, Verbaan H, Ring-Larsen H, Dalgard O. Eskesen AN, et al. Among authors: bjoro k. Eur J Gastroenterol Hepatol. 2012 Aug;24(8):890-6. doi: 10.1097/MEG.0b013e3283546efd. Eur J Gastroenterol Hepatol. 2012. PMID: 22584257

6

The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.

Dalgard O, Martinot-Peignoux M, Verbaan H, Bjøro K, Ring-Larsen H, Marcellin P. Dalgard O, et al. Among authors: bjoro k. PLoS One. 2015 Aug 28;10(8):e0120866. doi: 10.1371/journal.pone.0120866. eCollection 2015. PLoS One. 2015. PMID: 26317978 Free PMC article.

7

[Treatment of chronic hepatitis C].

Bell H, Dalgard O, Bjøro K, Hellum KB, Myrvang B. Bell H, et al. Among authors: bjoro k. Tidsskr Nor Laegeforen. 2002 Apr 10;122(9):926-8. Tidsskr Nor Laegeforen. 2002. PMID: 12082838 Free article. Norwegian. No abstract available.

8

Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma.

Melum E, Friman S, Bjøro K, Rasmussen A, Isoniemi H, Gjertsen H, Bäckman L, Oksanen A, Olausson M, Duraj FF, Ericzon BG. Melum E, et al. Among authors: bjoro k. J Hepatol. 2007 Dec;47(6):777-83. doi: 10.1016/j.jhep.2007.06.013. Epub 2007 Jul 23. J Hepatol. 2007. PMID: 17714825

9

Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation.

Melum E, Schrumpf E, Bjøro K. Melum E, et al. Among authors: bjoro k. Scand J Gastroenterol. 2006 May;41(5):592-6. doi: 10.1080/00365520500347113. Scand J Gastroenterol. 2006. PMID: 16638703

10

Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up.

Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H; Construct Group. Dalgard O, et al. Among authors: bjoro k. Eur Addict Res. 2002 Jan;8(1):45-9. doi: 10.1159/000049487. Eur Addict Res. 2002. PMID: 11818693

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

169 results

Search Page

Filters